



Biomarkers and Precision Medicine in Upper Gastrointestinal Malignancies

Guest Editor:

Prof. Dr. Morten Ladekarl

Department of Oncology, Aalborg
University Hospital, Hobrovej 18-
22, 9000 Aalborg, Denmark

Deadline for manuscript
submissions:

30 April 2025

Message from the Guest Editor

Dear Colleagues,

The current treatment of patients with upper gastrointestinal cancers is centred around chemotherapy and surgery, with a limited number of patients being candidates for immunotherapy or molecularly targeted treatment based on biomarker selection. The poor efficacy of treatment, late diagnoses, and the aggressive behavior of most cases contribute to the high mortality of these diseases.

To improve results, one major approach pursues the stratification of patients, according to the molecular characteristics for predicting treatment responses or resistance. Other strategies focus on novel biomarkers for early diagnosis, the detection of progression or relapse, or prognosis.

We invite researchers to publish studies within this topic in upper gastrointestinal malignancies, including esophageal-gastric, pancreatic, duodenal/small bowel, and hepatic-biliary cancers.

I look forward to receiving your contributions.

Prof. Dr. Morten Ladekarl
Guest Editor

